S
Stefan Faderl
Researcher at University of Texas MD Anderson Cancer Center
Publications - 586
Citations - 36426
Stefan Faderl is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Myeloid leukemia & Leukemia. The author has an hindex of 96, co-authored 577 publications receiving 34155 citations. Previous affiliations of Stefan Faderl include Penn State Milton S. Hershey Medical Center & Hackensack University Medical Center.
Papers
More filters
Journal ArticleDOI
Phase I study of TH-302, a hypoxia-activated cytotoxic prodrug, in subjects with advanced leukemias.
Marina Konopleva,Damian Handisides,Gustavo A. Lorente,Juliana Benito,Mary Ann Richie,Gautam Borthakur,Elias Jabbour,Stefan Faderl,Jorge E. Cortes,Stewart Kroll,Michael Andreeff,Hagop M. Kantarjian,Deborah A. Thomas +12 more
TL;DR: A phase 1 study of TH-302, a 2-nitroimidazole prodrug of the DNA alkylator, bromo-isophosphoramide mustard designed to be selectively activated in hypoxic conditions, was designed for advanced leukemias with no standard therapy options available and preliminary clinical activity was assessed.
Journal ArticleDOI
Time from Diagnosis to Treatment Initiation Predicts Survival in Acute Myeloid Leukemia (AML).
Mikkael A. Sekeres,Paul Elson,Xuemei Wang,Matt Kalaycio,Anjali S. Advani,Edward A. Copelan,Stefan Faderl,Hagop M. Kantarjian,Elihu H. Estey +8 more
TL;DR: AML should be considered a medical emergency in younger AML patients, as delaying induction therapy significantly affects CR rates and OS, and the harm in delaying therapy in young AML pts is offset by the potentially greater harm in giving standard therapy to those later found to have unfavorable cytogenetics.
Journal ArticleDOI
Pediatric-Based Therapy for Young Adults with Newly Diagnosed Lymphoblastic Leukemia.
Michael Rytting,Deborah A. Thomas,Anna Franklin,Elias Jabbour,William G. Wierda,Stefan Faderl,Robert J. Wells,Tapan M. Kadia,Farhad Ravandi,Alessandra Ferrajoli,Jorge E. Cortes,Susan O'Brien,Hagop M. Kantarjian +12 more
TL;DR: 48 young adult patients between the ages of 12 to 40 years with de novo Philadelphia chromosome negative ALL treated with the augmented Berlin-Frankfurt-Munster (BFM) chemotherapy regimen effectively induces remission, both by morphology and by flow cytometry.
Journal ArticleDOI
Final Update of Phase I-II Study of the Farnesyltransferase Inhibitor Tipifarnib in Combination with Idarubicin and Cytarabine for Patients with Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome.
John Delmonte,Hagop M. Kantarjian,Guillermo Garcia-Manero,Zeev Estrov,Farhad Ravandi,Srdan Verstovsek,Susan O'Brien,Charles Koller,Stefan Faderl,Deborah A. Thomas,John J. Wright,Jorge E. Cortes +11 more
TL;DR: It is concluded that Z combined with IA induces a high rate of CR in high-risk MDS or AML, but the outcome may not be superior to what is obtained with IA alone.
Journal ArticleDOI
The Heterogeneous Prognosis of Patients with Myelodysplastic Syndrome (MDS) and Chromosome 5 Abnormalities: How Does It Relate to the Original Lenalidomide Experience in MDS?.
Hagop M. Kantarjian,Susan O'Brien,Farhad Ravandi,Gautam Borthakur,Stefan Faderl,Carlos E. Bueso-Ramos,Lynne V. Abruzzo,Sherry Pierce,Jianqin Shan,Jean Pierre J. Issa,Guillermo Garcia-Manero +10 more
TL;DR: This study provides baseline expectations of outcome in different MDS subsets and deletion 5q, which could be used for comparative purposes with the lenalidomide experience to define the prognosis in MDS and deletion5q with or without other cytogenetic abnormalities.